Have you tested hsCRP? A 2025 ACC Scientific Statement on inflammation in CVD recommends intensified management in patients with increased inflammatory risk.1*
The global POSEIDON study assembles real‑world evidence from 18,000+ patients across 18 countries. Findings put the global burden of CV inflammation in HF on record.1 Learn more at ESC Congress 2026, Hall A2 Stand
T100.
Show more
The POSEIDON study found that CV inflammation remained prevalent despite standard of care and despite the presence of comorbid hypertension or T2D. Identify inflammatory risk by testing hsCRP.
Have you tested hsCRP? A 2025 ACC Scientific Statement on inflammation in CVD recommends intensified management in patients with increased inflammatory risk.1*
ESC and ACC/AHA recognise hsCRP as a modifier and enhancer of CVD risk. Is CV Inflammation guilty?
CV inflammation leaves a trail, test hsCRP to find it. ESC/EAS and ACC/AHA guidelines recognise hsCRP as a biomarker of inflammation in CV risk assessment.1,2 Find out more about the latest guideline updates at ESC Hall A2 Stand T100.
Show more
The latest data, connecting with peers, finding the best coffee - what's on your ESC 2026 bingo card? Meet us in Munich and visit us on CongressHub!
Obesity and cardiovascular inflammation remain urgent challenges. At ESC Congress 2026, we're spotlighting science that drives innovation - and lasting health.
Mark your calendar - it's time for ESC 2026! Stay informed about the latest innovations within cardiovascular disease and obesity by visiting us in Munich and online on CongressHub! 👇
